SCHEMBL721487

SCHEMBL721487

COc1cc(N)cc(-c2cc3nccc(-c4ccccc4)c3o2)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 7/20 0.45
LCK P06239 1/20 0.41
CASP3 P42574 1/20 0.38
SENP7 Q9BQF6 1/20 0.38
NTRK1 P04629 1/20 0.38
TOP1 P11387 1/20 0.37
NUDT1 P36639 1/20 0.36
ALDH1A1 P00352 3/20 0.36
ADORA1 P30542 3/20 0.36
MAPT P10636 2/20 0.36
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
MEN1 O00255 1/20 0.36
CRHBP P24387 1/20 0.36
KMT2A Q03164 1/20 0.36
CRHR2 Q13324 1/20 0.36
FLT1 P17948 1/20 0.36
FLT4 P35916 1/20 0.36
KDR P35968 1/20 0.36
KDM4E B2RXH2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL724917 0.85 TOP1 (0.48) ADORA2ATOP1ALDH1A1ADORA1MAPT
SCHEMBL12503587 0.84 CHEK2 (0.41) CASP3SENP7TOP1ALDH1A1MAPT
SCHEMBL721977 0.83 KDR (0.38) KDR
SCHEMBL12503586 0.81 ADORA2A (0.45) ADORA2ALCKNTRK1NUDT1ALDH1A1
SCHEMBL723840 0.80 CCNB2 (0.48) TOP1ALDH1A1MAPTNPC1RAB9A
SCHEMBL722839 0.80 PDE4C (0.51) ALDH1A1MEN1KMT2AFLT1FLT4
SCHEMBL27920129 0.79 CYP1A1 (0.48) ADORA2ATOP1NUDT1ALDH1A1ADORA1
SCHEMBL12503589 0.79 ALDH1A1 (0.46) ADORA2ANTRK1ALDH1A1ADORA1MAPT
SCHEMBL723435 0.79 EGFR (0.47) ALDH1A1MAPTMEN1KMT2AKDM4E
SCHEMBL722854 0.78 FAAH (0.41) ADORA2ANUDT1MAPTNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP claimed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US claimed
US-20130225569-A1 FUROPYRIDINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US claimed
EP-2609100-A2 FUROPYRIDINE DERIVATIVES Merck Patent GmbH (DE) 2013-07-03 EP claimed
WO-2012025187-A2 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2012-03-01 WO claimed
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP disclosed
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP disclosed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US disclosed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US disclosed
WO-2012025187-A2 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2012-03-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225569-A1 FUROPYRIDINE DERIVATIVES SYK, FCGRT, SSB ADORA2A 1547/4885LCK 8/4885CASP3 933/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.